Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Reumatología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Were Given Canakinumab at the Time of Gout Flare
INTERVENTIONAL
Inicio: 5 de jun de 2009
ID: NCT00927810
Completado
Fase 2
ClinicalTrials.gov
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone
INTERVENTIONAL
Inicio: 17 de jul de 2013
ID: NCT01888874
Completado
Fase 3
ClinicalTrials.gov
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de ene de 2012
ID: NCT01521923
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind Study of the Effect of Tocilizumab on Reduction in Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
INTERVENTIONAL
Inicio: 1 de abr de 2005
ID: NCT00106574
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX
INTERVENTIONAL
Inicio: 23 de mar de 2016
ID: NCT02706951
Completado
Fase 2
ClinicalTrials.gov
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 7 de sept de 2012
ID: NCT01649765
Completado
Fase 2
ClinicalTrials.gov
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
INTERVENTIONAL
Inicio: 1 de oct de 2008
ID: NCT00785928
Completado
Fase 2
ClinicalTrials.gov
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
INTERVENTIONAL
Inicio: 20 de oct de 2016
ID: NCT02847598
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects With Axial Spondyloarthritis Followed by a Remission-Withdrawal Period
INTERVENTIONAL
Inicio: 26 de nov de 2019
ID: NCT04169373
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
INTERVENTIONAL
Inicio: 6 de jun de 2016
ID: NCT02760407
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
INTERVENTIONAL
Inicio: 13 de jul de 2021
ID: NCT04908202
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Dose Range Finding Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy
INTERVENTIONAL
Inicio: 31 de oct de 2012
ID: NCT01679951
Completado
Fase 2
ClinicalTrials.gov
A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
INTERVENTIONAL
Inicio: 1 de mar de 2013
ID: NCT01715896
Completado
Fase 3
ClinicalTrials.gov
A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis
INTERVENTIONAL
Inicio: 3 de mar de 2015
ID: NCT02376790
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
INTERVENTIONAL
Inicio: 30 de ago de 2016
ID: NCT02889796
Completado
Fase 2
ClinicalTrials.gov
A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
INTERVENTIONAL
Inicio: 10 de ene de 2018
ID: NCT03371251
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis
INTERVENTIONAL
Inicio: 10 de ago de 2020
ID: NCT04221477
Completado
Fase 3
ClinicalTrials.gov
Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome
INTERVENTIONAL
Inicio: 1 de mar de 2011
ID: NCT01237587
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GLPG3667 in Adult Subjects With Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 28 de jun de 2023
ID: NCT05856448
Reclutando
Fase 4
ClinicalTrials.gov
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the Efficacy and Safety of Belimumab Administered Subcutaneously in Adult Participants With Early Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 6 de jun de 2024
ID: NCT06411249
Anterior
1
...
12
13
14
...
434
Siguiente
Filtros